Publication

# corresponding author; * contribute equally

35. Lindell, E., Guo, J., Zhao, M., Rameika, N., Zhong, L., Bergström, T., Svanberg, S., Chowdhury, A. I., Bergsten, P., Bexell, D., Swartling, F. J., Sjöblom, T., & Zhang, X#. Identification of a small molecule targeting EPLIN as a novel strategy for the treatment of neuroblastoma. Cell Death & Disease. (2025)

34. Rameika, N., Tsiara, I., Zhang, X., Rendo, V., Kundu, S., Correia, M. S. P., Stoimenov, I., Globisch, D., & Sjöblom, T. NAT2 activity increases cytotoxicity of anthracycline antibiotics and HDAC inhibitors. Biochimica et Biophysica Acta - Molecular Basis of Disease. (2025)

33. Zhang, X., Rameika, N., Zhong, L., Rendo, V., Kundu, S., Nuciforo, S., Dupuis, J., Al Azhar, M., Tsiara, I., Seeburger, P., Al Nassralla, S., Ljungström, V., Svensson, R., Stoimenov, I., Artursson, P., Heim, M. H., Globisch, D., & Sjöblom, T. Loss of CYP2D6 sensitizes hepatocellular carcinomas and neuroblastomas to talazoparib. eBioMedicine. (2024)

32. Lindell, E., & Zhang, X#. Exploring the enigma: The role of the epithelial protein lost in neoplasm in normal physiology and cancer pathogenesis. International Journal of Molecular Sciences. (2024)

31. Wang, X., Mao, K., Zhang, X., Zhang, Y., Yang, Y.-G., & Sun, T. Red blood cell-derived nanocarrier drug delivery system: A promising strategy for tumor therapy. Interdisciplinary Medicine. (2024)

30. Lu, X., Zhong, L., Lindell, E., Veanes, M., Guo, J., Zhao, M., Salehi, M., Swartling, F., Chen, X., Sjöblom, T., & Zhang, X#. Identification of ATF3 as a novel protective signature of quiescent colorectal tumor cells. Cell Death & Disease. (2023)

29. Zhong, L., Zhao, Z. P., & Zhang, X#. Genetic differences between primary and metastatic cancer: A pan-cancer whole genome comparison study. Signal Transduction and Targeted Therapy. (2023)

28. Peng, X. R., Shi, J. Y., Zhao, Z., Tong, R. S., Zhang, X#., & Zhong#, L. Emetine, a small molecule natural product, displays potent anti-gastric cancer activity via regulation of multiple signaling pathways. Cancer Chemotherapy and Pharmacology. (2023)

27. Lindell, E., Zhong, L., & Zhang, X#. Quiescent cancer cells—A potential therapeutic target to overcome tumor resistance and relapse. International Journal of Molecular Sciences. (2023)

26. Zhang, X., Akcan, E., Correia, M., Rameika, N., Kundu, S., Stoimenov, I., Rendo, V., Eriksson, A., Haraldsson, M., Globisch, D., & Sjöblom, T. Enhanced cytotoxicity of a novel family of ATPase inhibitors in colorectal cancer cells with high NAT2 activity. Biochemical Pharmacology. (2022)

25. Jakobsson, A., Kundu, S., Guo, J., Chowdhury, A., Zhao, M., Lindell, E., Bergsten, P., Swartling, F., Sjöblom, T., & Zhang, X#. Iron chelator VLX600 inhibits mitochondrial respiration and promotes sensitization of neuroblastoma cells in nutrition-restricted conditions. Cancers. (2022)

24. Zhang, X., Shetty, M., Clemente, V., Linder, S., & Bazzaro, M. Targeting mitochondrial metabolism in clear cell carcinoma of the ovaries. International Journal of Molecular Sciences. (2021)

23. Zhang, X., & Sjöblom, T. Targeting loss of heterozygosity: A novel paradigm for cancer therapy. Pharmaceuticals. (2021)

22. Habicht, J., Mooneyham, A., Hoshino, A., Shetty, M., Zhang, X., Emmings, E., Yang, Q., Coombes, C., Gardner, M. K., & Bazzaro, M. UNC-45A breaks the microtubule lattice independently of its effects on non-muscle myosin II. Journal of Cell Science. (2021)

21. Pellegrini, P., Selvaraju, K., Faustini, E., Mofers, A., Zhang, X., Ternerot, J., Schubert, A., Linder, S., & D’Arcy, P. D. Induction of ER stress in acute lymphoblastic leukemia cells by the deubiquitinase inhibitor VLX1570. International Journal of Molecular Sciences. (2020)

20. Zhang, X., Linder, S., & Bazzaro, M. Drug development targeting the UPS for the treatment of human cancers. Cancers. (2020)

19. Zhang, X., Espinosa, B., Saei, A., D’Arcy, P., Zubarev, R., & Linder, S. Oxidative stress induced by the deubiquitinase inhibitor b-AP15 is associated with mitochondrial impairment. Oxidative Medicine and Cellular Longevity. (2019)

18. Zhang, X., Selvaraju, K., Saei, A. A., D’Arcy, P., Zubarev, R. A., Arnér, E. S. J., & Linder, S. Repurposing of auranofin: Thioredoxin reductase remains a primary target of the drug. Biochimie. (2019)

17. Habicht, J., Mooneyham, A., Shetty, M., Zhang, X., Shridhar, V., Winterhoff, B., Zhang, Y., Cepela, J., Starr, T., Lou, E., & Bazzaro, M. UNC-45A is preferentially expressed in epithelial cells and binds to and co-localizes with interphase MTs. Cancer Biology & Therapy. (2019)

16. Hillert, E.-K., Brjnic, S., Zhang, X., Mazurkiewicz, M., Mofers, A., Saei, A. A., Zubarev, R., Linder, S., & D’Arcy, P. Proteasome inhibitor b-AP15 induces enhanced proteotoxicity by inhibiting cytoprotective aggresome formation. Cancer Letters. (2019)

15. Zhang, X., Pellegrini, P., Saei, A. A., Hillert, E.-K., Mazurkiewicz, M., Olofsson, M. H., Zubarev, R. A., D’Arcy, P., & Linder, S. The deubiquitinase inhibitor b-AP15 induces strong proteotoxic stress and mitochondrial damage. Biochemical Pharmacology. (2019)

14. Stafford, W. C., Peng, X., Hägg Olofsson, M., Zhang, X., Luci, D. K., Lu, L., Cheng, Q., Trésaugues, L., Dexheimer, T. S., Coussens, N. P., Augsten, M., Martinsson Ahlzén, H.-S., Orwar, O., Östman, A., Stone-Elander, S., Maloney, D. J., Jadhav, A., Simeonov, A., Linder, S., & Arnér, E. S. J. Inhibition of cytosolic thioredoxin reductase 1 as a mechanistic basis for anticancer therapy. Science Translational Medicine. 2018

13. Zhang, X., Mofers, A., Hydbring, P., Hägg-Olofsson, M., Guo, J., Linder, S., & D'Arcy, P. MYC is downregulated by a mitochondrial checkpoint mechanism. Oncotarget. 2017

12. Zhang, X., De Milito, A., Demiroglu-Zegeroglu, A., Gullbo, J., D’Arcy, P., & Linder, S. Eradicating quiescent tumor cells by targeting mitochondrial bioenergetics. Trends in Cancer. 2016

11. Mao, Y., van Hoef, V., Zhang, X., Wennerberg, E., Lorent, J., Witt, K., Masvidal Sanz, L., Liang, S., Murray, S., Larsson, O., Kiessling, R., & Lundqvist, A. IL-15 activates mTOR and primes stress-activated gene-expression leading to prolonged antitumor capacity of NK cells. Blood. 2016

10. Fryknäs, M., Zhang, X., Bremberg, U., Senkowski, W., Hägg Olofsson, M., Brandt, P., Persson, I., D’Arcy, P., Gullbo, J., Nygren, P., Schughart, L. K., Linder, S., & Larsson, R. Iron chelators target both proliferating and quiescent cancer cells. Scientific Reports. 2016

9. Ma, R., Karthik, G.-M., Lövrot, J., Haglund, F., Rosin, G., Katchy, A., Zhang, X., Robenhorst, U., Hilliges, C., Linder, S., Frisell, J., Williams, C., Toftgård, R., Fredriksson, I., & Hartman, J. Estrogen receptor β maintains breast cancer stem cells and is a potential target for endocrine therapy. Journal of the National Cancer Institute. 2016

8. Zhang, X., De Milito, A., Hägg Olofsson, M., Gullbo, J., D’Arcy, P., & Linder, S. Targeting mitochondrial function to treat quiescent tumor cells in solid tumors. International Journal of Molecular Sciences. 2015

7. Senkowski, W., Zhang, X., Hägg Olofsson, M., & Isacson, R. Three-dimensional cell culture-based screening identifies the anthelminthic drug nitazoxanide as a candidate for treatment of solid tumors. Molecular and Cellular Therapeutics. 2015

6. Zhang, X*., Fryknäs, M.*, Hernlund, E., Fayad, W., De Milito, A., Hägg Olofsson, M., Gogvadze, V., Dang, L., Påhlman, S., Schughart, L. A. K., Rickardson, L., D’Arcy, P., Gullbo, J., Nygren, P., Larsson, R., & Linder, S. Induction of mitochondrial dysfunction as a strategy for targeting tumour cells in metabolically compromised microenvironments. Nature Communications. 2014

5. Wang, X., Stafford, W., Mazurkiewicz, M., Fryknäs, M., Brjnic, S., Zhang, X., Gullbo, J., Larsson, R., Arnér, E., D'Arcy, P., & Linder, S. The 19S deubiquitinase inhibitor b-AP15 is enriched in cells and elicits rapid commitment to cell death. Molecular Pharmacology. 2014

4. Brnjic, S., Mazurkiewicz, M., Fryknäs, M., Sun, C., Zhang, X., Larsson, R., D'Arcy, P., & Linder, S. Induction of tumor cell apoptosis by a proteasome deubiquitinase inhibitor is associated with oxidative stress. Antioxidants & Redox Signaling. 2013

3. Aftab, O., Fryknäs, M., Zhang, X., Hammerling, U., Linder, S., Larsson, R., & Gustafsson, M. Label‐free detection and dynamic monitoring of drug-induced intracellular vesicle formation enabled using a 2-dimensional matched filter. Autophagy. 2013

2. Hernlund, E., Olofsson, M. H., Fayad, W., Fryknäs, M., Lesiak-Mieczkowska, K., Zhang, X., Brnjic, S., Schmidt, V., D'Arcy, P., Sjöblom, T., De Milito, A., Larsson, R., & Linder, S. The phosphoinositide 3-kinase/mammalian target of rapamycin inhibitor NVP-BEZ235 is effective in inhibiting regrowth of tumour cells after cytotoxic therapy. European Journal of Cancer. 2012

1. Marino, M. L., Pellegrini, P., Di Lernia, G., Djavaheri-Mergny, M., Brnjic, S., Zhang, X., Hägg, M., Linder, S., Fais, S., Codogno, P., & De Milito, A. Autophagy is a protective mechanism for human melanoma cells under acidic stress. Journal of Biological Chemistry. 2012